According to the business intelligence report titled ‘Global Erythropoietin Drugs Market Size study, By Drug Class (Biologics, Biosimilars), By Product (Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa, Others), By Application (Cancer, Hematology, Neurology and Renal Diseases) and Regional Forecasts 2021-2027’, available with Market Study Report, global erythropoietin drugs market was assessed at USD 11.05 billion in 2020 and is estimated to be worth USD 23.38 billion by 2027, growing at an annual rate of 11.3% CAGR between 2021-2027.
 

Increasing incidence of chronic kidney diseases, growing number of HIV & anemia patients, and rising pool of patients undergoing chemotherapy are the key growth drivers for global erythropoietin drugs industry.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/3891231/
 

As per National Kidney Foundation, in 2018, kidney disease affected 37 million people in U.S.A. and 785,883 people died from kidney failure in the same year. Heart disease, diabetes, high blood pressure, and obesity are the primary causes of kidney disease.
 

For the unaware, erythropoietin is a hormone produced by the kidney and is crucial for the formation of red blood cells by the bone marrow. The rise in red blood cells raises the oxygen carrying capacity of the blood. 
 

While rising number of diabetics and heart patients is raising demand for erythropoietin drugs, high cost of manufacturing will act as a challenge for businesses in this domain.
 

Based on drug class, worldwide erythropoietin drugs market is divided into biosimilars, and biologics. Speaking of product gamut, the industry is split into epoetin-beta, epoetin-alpha, darbepoetin-alfa, and others. As per application scope, the business sphere is bifurcated into cancer, neurology, hematology, and renal diseases.
 

From the regional frame of reference, North America held majority market share in the recent past, owing to surging healthcare expenditure, higher per capita income, and large pool of patients with chronic kidney disease.
 

Meanwhile, Asia Pacific market is slated to expand significantly between 2021-2027, due to growing government & private investment in healthcare sector, rising cases of HIV & anemia in emerging economies, and increasing disposable incomes.
 

Leading players profiled in the global erythropoietin report are Celltrion Inc., Amgen Inc., Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., F. Hoffmann-La Roche AG, Sun Pharmaceutical Industries Ltd., LG Life Sciences Ltd., Intas Pharmaceuticals Ltd., and Biocon Limited.